ClinicalTrialsFinder
RecruitingPhase 4NCT06558188

Combined Anabolic Therapy

Combined Anabolic Therapy Study

Sponsor

Massachusetts General Hospital

Enrollment

50 participants

Start Date

Feb 3, 2025

Study Type

INTERVENTIONAL

Conditions

OsteoporosisOsteoporosis, Postmenopausal

Summary

In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.

Eligibility

Sex: FEMALEMin Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Romosozumab and a drug called Teriparatide for people with osteoporosis and osteoporosis, postmenopausal. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 45 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRomosozumab

romosozumab 210 milligrams monthly

DRUGTeriparatide

teriparatide 20 micrograms daily

Locations(1)

Massachusetts General Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06558188

Related Trials

Sequential Therapies After Osteoanabolic Treatment

NCT061647958 locations

U.S. Prospective Evaluation of EPIONE Device for Percutaneous MSK Procedures

NCT073255783 locations

The Optimised Use of Romozosumab Study

NCT060592221 location

Functional Muscle-Bone Incongruity Index (FKUI): A Prospective Observational Study

NCT076770331 location

Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?

NCT076770721 location